Cargando…
Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry
BACKGROUND: Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2 triptans (‘triptan resistance’) could be considered eligibl...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563311/ https://www.ncbi.nlm.nih.gov/pubmed/37817093 http://dx.doi.org/10.1186/s10194-023-01676-0 |
_version_ | 1785118312711061504 |
---|---|
author | Ruscheweyh, Ruth Gossrau, Gudrun Dresler, Thomas Freilinger, Tobias Förderreuther, Stefanie Gaul, Charly Kraya, Torsten Neeb, Lars Ruschil, Victoria Straube, Andreas Scheidt, Jörg Jürgens, Tim Patrick |
author_facet | Ruscheweyh, Ruth Gossrau, Gudrun Dresler, Thomas Freilinger, Tobias Förderreuther, Stefanie Gaul, Charly Kraya, Torsten Neeb, Lars Ruschil, Victoria Straube, Andreas Scheidt, Jörg Jürgens, Tim Patrick |
author_sort | Ruscheweyh, Ruth |
collection | PubMed |
description | BACKGROUND: Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2 triptans (‘triptan resistance’) could be considered eligible for treatment with the novel medications from the ditan and gepant groups. There is little data on the frequency of ‘triptan resistance’. METHODS: We used patient self-report data from the German Migraine and Headache Society (DMKG) Headache Registry to assess triptan response and triptan efficacy and/or tolerability failure. RESULTS: A total of 2284 adult migraine patients (females: 85.4%, age: 39.4 ± 12.8 years) were included. 42.5% (n = 970) had failed ≥ 1 triptan, 13.1% (n = 300) had failed ≥ 2 triptans (meeting the EHF definition of ‘triptan resistance’), and 3.9% (n = 88) had failed ≥ 3 triptans. Compared to triptan responders (current use, no failure, n = 597), triptan non-responders had significantly more severe migraine (higher frequency (p < 0.001), intensity (p < 0.05), and disability (p < 0.001)), that further increased with the level of triptan failure. Responders rates were highest for nasal and oral zolmitriptan, oral eletriptan and subcutaneous sumatriptan. CONCLUSION: In the present setting (specialized headache care in Germany), 13.1% of the patients had failed ≥ 2 triptans. Triptan failure was associated with increased migraine severity and disability, emphasizing the importance of establishing an effective and tolerable acute migraine medication. Acute treatment optimization might include switching to one of the triptans with the highest responder rates and/or to a different acute medication class. TRIAL REGISTRATION: The DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10194-023-01676-0. |
format | Online Article Text |
id | pubmed-10563311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-105633112023-10-11 Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry Ruscheweyh, Ruth Gossrau, Gudrun Dresler, Thomas Freilinger, Tobias Förderreuther, Stefanie Gaul, Charly Kraya, Torsten Neeb, Lars Ruschil, Victoria Straube, Andreas Scheidt, Jörg Jürgens, Tim Patrick J Headache Pain Research BACKGROUND: Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2 triptans (‘triptan resistance’) could be considered eligible for treatment with the novel medications from the ditan and gepant groups. There is little data on the frequency of ‘triptan resistance’. METHODS: We used patient self-report data from the German Migraine and Headache Society (DMKG) Headache Registry to assess triptan response and triptan efficacy and/or tolerability failure. RESULTS: A total of 2284 adult migraine patients (females: 85.4%, age: 39.4 ± 12.8 years) were included. 42.5% (n = 970) had failed ≥ 1 triptan, 13.1% (n = 300) had failed ≥ 2 triptans (meeting the EHF definition of ‘triptan resistance’), and 3.9% (n = 88) had failed ≥ 3 triptans. Compared to triptan responders (current use, no failure, n = 597), triptan non-responders had significantly more severe migraine (higher frequency (p < 0.001), intensity (p < 0.05), and disability (p < 0.001)), that further increased with the level of triptan failure. Responders rates were highest for nasal and oral zolmitriptan, oral eletriptan and subcutaneous sumatriptan. CONCLUSION: In the present setting (specialized headache care in Germany), 13.1% of the patients had failed ≥ 2 triptans. Triptan failure was associated with increased migraine severity and disability, emphasizing the importance of establishing an effective and tolerable acute migraine medication. Acute treatment optimization might include switching to one of the triptans with the highest responder rates and/or to a different acute medication class. TRIAL REGISTRATION: The DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10194-023-01676-0. Springer Milan 2023-10-10 /pmc/articles/PMC10563311/ /pubmed/37817093 http://dx.doi.org/10.1186/s10194-023-01676-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ruscheweyh, Ruth Gossrau, Gudrun Dresler, Thomas Freilinger, Tobias Förderreuther, Stefanie Gaul, Charly Kraya, Torsten Neeb, Lars Ruschil, Victoria Straube, Andreas Scheidt, Jörg Jürgens, Tim Patrick Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry |
title | Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry |
title_full | Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry |
title_fullStr | Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry |
title_full_unstemmed | Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry |
title_short | Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry |
title_sort | triptan non-response in specialized headache care: cross-sectional data from the dmkg headache registry |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563311/ https://www.ncbi.nlm.nih.gov/pubmed/37817093 http://dx.doi.org/10.1186/s10194-023-01676-0 |
work_keys_str_mv | AT ruscheweyhruth triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT gossraugudrun triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT dreslerthomas triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT freilingertobias triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT forderreutherstefanie triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT gaulcharly triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT krayatorsten triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT neeblars triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT ruschilvictoria triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT straubeandreas triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT scheidtjorg triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry AT jurgenstimpatrick triptannonresponseinspecializedheadachecarecrosssectionaldatafromthedmkgheadacheregistry |